NEWS & VIEWS STROKE
the use of fixed-dose high-intensity or moderate-intensity statin therapy in prespecified patient groups.5 In any case, no major randomized controlled trial has specifically tested the benefits of treating patients with stroke or TIA according to LDL targets, so the value of aiming for a given LDL target for the prevention of secondary stroke in these patients has not been firmly established.1 Regardless of LDL level, however, the fact that less than 50% of high-risk stroke patients in the GWTGStroke Registry were on a lipid modifier at the time of their index stroke or TIA is troubling, and it is conceivable that routine care outside the GWTG-participating hospital network is even worse. Second, the advice to aim for an LDL cholesterol level
the use of fixed-dose high-intensity or moderate-intensity statin therapy in prespecified patient groups.5 In any case, no major randomized controlled trial has specifically tested the benefits of treating patients with stroke or TIA according to LDL targets, so the value of aiming for a given LDL target for the prevention of secondary stroke in these patients has not been firmly established.1 Regardless of LDL level, however, the fact that less than 50% of high-risk stroke patients in the GWTGStroke Registry were on a lipid modifier at the time of their index stroke or TIA is troubling, and it is conceivable that routine care outside the GWTG-participating hospital network is even worse. Second, the advice to aim for an LDL cholesterol level
